Tests stented heart artery treatment alongside valve replacement in people with aortic stenosis
Tests stent procedures on narrowed heart arteries versus medicine alone in aortic stenosis patients.
Key facts
- Who runs it
- University of British Columbia
- Where
- Akron, Atlanta, Atlantis, Boise, Boston, Buffalo, Burlington, Camden, Charlotte, Chicago, Clackamas, Columbia, Columbus, Elkhart, Fort Wayne, Gainesville, Germantown, Green Bay, Houston, Huntsville, Jacksonville, Kansas City, Kingsport, Knoxville, Lansing, Lebanon, Lincoln, Memphis, Miami, Milwaukee, Mineola, Minneapolis, New York, Oklahoma City, Overland Park, Palo Alto, Phoenix, Plano, Providence, Redlands, Ridgewood, Round Rock, Royal Oak, Saginaw, Saint Cloud, Santa Barbara, St Louis, Syracuse, The Bronx, Torrance, Wichita, and Ypsilanti, United StatesSee the 55 sitesAlso in 1 other country, 17 sites
- Trial code
- Registry title
- Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement
- Status
- Recruiting
- People taking part
- 4,000 people, planned
- Started
- 19 Dec 2020
- Planned end
- 1 Apr 2026
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Percutaneous Coronary Intervention (PCI)
- Record updated
- 24 July 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with symptomatic aortic valve stenosis and coronary artery disease who have just had a successful transfemoral TAVR valve replacement. It compares extra stenting of the coronary arteries with medicines alone.
- Sex
- All sexes can join.
- Disease stage
- Symptomatic aortic valve stenosis (NYHA class 2 or higher, or an abnormal exercise test), plus at least 1 coronary artery narrowing of 70% or more in a vessel at least 2.5 mm wide that can be treated with a stent.
- Earlier treatment
- A successful transfemoral TAVR with a single valve within the past 96 hours. No stenting within 90 days before TAVR or during the TAVR. No prior bypass surgery or surgical valve replacement.
Main reasons for not taking part
- Prior coronary bypass surgery or surgical valve replacement
- Heart attack, stroke or mini-stroke within 90 days
- Severe left heart pumping weakness (LVEF below 30%) or severe mitral regurgitation (above 3+)
- Kidney function eGFR below 30 ml/min and/or kidney replacement treatment
- Other illness reducing life expectancy to under 5 years, or anything stopping 5-year follow-up
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Symptomatic aortic valve stenosis prior to TAVR (NYHA Functional Class ≥ 2 OR Abnormal exercise test with severe SOB, abnormal BP response, or arrhythmia); AND
- CAD defined as: at least 1 coronary artery lesion of ≥70% visual angiographic diameter stenosis in a native segment ≥2.5 mm in diameter that is not a CTO and is amenable to treatment with PCI; AND
- Consensus by the Local Multidisciplinary Heart Team that the patient is suitable for elective transfemoral TAVR with a balloon expandable transcatheter heart valve AND would receive a bypass with an anastomosis distal to the coronary artery lesion(s) if they were undergoing SAVR; Local Multidisciplinary Heart Teams are expected to follow current clinical guidelines for selection of patients for TAVR with an eligible patient generally expected to have:; [AVA ≤ 1.0 cm2 OR AVA index ≤ 0.6 cm2/m2]; OR; [Jet velocity ≥ 4.0 m/s OR mean gradient ≥ 40 mmHg]; OR; patients without these criteria may undergo TAVR if the Local Multidisciplinary Heart Team concludes it is appropriate; AND
- Successful transfemoral TAVR, defined as the implantation of a single transcatheter aortic valve within the past 96 hours with freedom from more than minimal aortic insufficiency, stroke, or major vascular complications
Who cannot take part
- PCI already performed within 90 days prior to TAVR or at the same time as the index transfemoral TAVR procedure
- Planned surgical revascularization of coronary artery lesion(s)
- Prior coronary artery bypass grafting surgery or surgical valve replacement
- Acute myocardial infarction within 90 days
- Stroke or transient ischemic attack within 90 days
- Severe left ventricular dysfunction (LVEF < 30%)
- Renal insufficiency (eGFR < 30 ml/min) and/or renal replacement Rx
- Non-cardiovascular co-morbidity reducing life expectancy to < 5 years
- Planned PCI of coronary artery lesion(s)
- Any factor precluding 5-year follow-up
- Severe mitral regurgitation (> 3+)
- Low coronary takeoff (high risk for coronary obstruction)
- Hemodynamic or respiratory instability
Where in United States
Also in 1 other country, 17 sites
- Summa Health SystemAkron, United StatesContact: Peter Bittenbender, MDTaking people
- PiedmontAtlanta, United StatesContact: Pradeep Yadav, MDTaking people
- JFK Medical CenterAtlantis, United StatesContact: Mark Rothenberg, MDTaking people
- St. Alphonsus Regional Medical CenterBoise, United StatesContact: Joseph Walsh, MDTaking people
- Massachusetts General HospitalBoston, United StatesContact: Nilay Patel, MDTaking people
- Tufts MedicalBoston, United StatesContact: Charles Resor, MDTaking people
- University at BuffaloBuffalo, United StatesContact: Vijay Iyer, MDTaking people
- University of Vermont Medical CenterBurlington, United StatesContact: Tanush Gupta, MDTaking people
- Our Lady of LourdesCamden, United StatesContact: Ibrahim Moussa, MDTaking people
- Novant Health Heart and Vascular InstituteCharlotte, United StatesContact: Oluseun Alli, MDTaking people
- Ascension Alexian BrothersChicago, United StatesContact: Andrei Pop, MDTaking people
- Kaiser Permanente NorthwestClackamas, United StatesContact: Abhimanyu UberoiTaking people
- Boone HospitalColumbia, United StatesContact: Joss Fernandez, MDTaking people
- Mount CarmelColumbus, United StatesContact: Noah Jones, MDTaking people
- Midwest Cardiovascular Research and Education FoundationElkhart, United StatesContact: Troy Weirick, MDTaking people
- Parkview Research CenterFort Wayne, United StatesContact: Roy W Robertson, MDTaking people
- Northeast Georgia Health SystemGainesville, United StatesContact: Ronnie RamadanTaking people
- Methodist Le Bonheur HealthcareGermantown, United StatesContact: Mehul Patel, MDTaking people
- Bellin Health SystemGreen Bay, United StatesContact: Jason RicciTaking people
- HCA Houston Healthcare Medical CenterHouston, United StatesContact: Pranav Loyalka, MDTaking people
- Huntsville Heart CenterHuntsville, United StatesContact: Alex Vasquez, MDTaking people
- Baptist Health - JacksonvilleJacksonville, United StatesContact: Sidd Wayangankar, MDTaking people
- University of Kansas Medical CenterKansas City, United StatesContact: Peter Tadros, MDTaking people
- Ballad Health CVA Heart InstituteKingsport, United StatesContact: Mark Aziz, MDTaking people
- Parkwest Medical CenterKnoxville, United StatesContact: Ayaz Rahman, MDTaking people
- Sparrow Clinical Research InstituteLansing, United StatesContact: Mohammad Qintar, MDTaking people
- Dartmouth Hitchcock Medical CenterLebanon, United StatesContact: James DeVries, MDTaking people
- Bryan HeartLincoln, United StatesContact: Matthew Johnson, MDTaking people
- Cardiovascular Surgery Clinic/Baptist MemorialMemphis, United StatesContact: Basil Paulus, MDTaking people
- Miami Cardiac and Vascular/Baptist HospitalMiami, United StatesContact: Ramon QuesadaTaking people
- Ascension Columbia St. Mary'sMilwaukee, United StatesContact: Brad Stair, MDTaking people
- NYU Langone Hospital - Long IslandMineola, United StatesContact: Richard Schwartz, DOTaking people
- University of Minnesota Medical CenterMinneapolis, United StatesContact: Gregory Helmer, MDTaking people
- Columbia University Medical CenterNew York, United StatesContact: Vivian Ng, MDTaking people
- Mount SinaiNew York, United StatesContact: Samin Sharma, MDTaking people
- Oklahoma HeartOklahoma City, United StatesContact: Mohammad Ghani, MDTaking people
- Midwest Heart and VascularOverland Park, United StatesContact: Bangalore Deepak, MDTaking people
- Veteran Affairs Palo Alto Health Care SystemPalo Alto, United StatesContact: Celina Yong, MDTaking people
- Arizona Cardiovascular ResearchPhoenix, United StatesContact: Hursh Naik, MDTaking people
- Baylor Scott & White - PlanoPlano, United StatesContact: Srini Potluri, MDTaking people
- Rhode Island HospitalProvidence, United StatesContact: Paul Gordon, MDTaking people
- Loma Linda UniversityRedlands, United StatesContact: Ken Jutzy, MDTaking people
- Valley HospitalRidgewood, United StatesContact: Raj Tayal, MDTaking people
- Baylor Scott & White - Round RockRound Rock, United StatesContact: Jose Condado, MDTaking people
- William Beaumont HospitalRoyal Oak, United StatesContact: Amr Abbas, MDTaking people
- Ascension St. Mary'sSaginaw, United StatesContact: Safwan Kassas, MDTaking people
- Centracare Heart and Vascular CenterSaint Cloud, United StatesContact: Thom Dahle, MDTaking people
- Santa Barbara Cottage HospitalSanta Barbara, United StatesContact: Michael Shenoda, MDTaking people
- Missouri BaptistSt Louis, United StatesContact: Gus Theodos, MDTaking people
- St Louis UniversitySt Louis, United StatesContact: Kishore Harjai, MDTaking people
- St. Joseph's HospitalSyracuse, United StatesContact: Ayman Iskander, MDTaking people
- Montefiore Medical CenterThe Bronx, United StatesContact: Mark Menegus, MDTaking people
- Torrance Memorial Medical CenterTorrance, United StatesContact: Salman Azam, MDTaking people
- Cardiovascular Research Institute of KansasWichita, United StatesContact: Bassem Chehab, MDTaking people
- St. Joseph Mercy Health SystemYpsilanti, United StatesContact: Mansoor A Qureshi, MDTaking people
About the trial
What the trial wants to find out
Patients undergoing transcatheter aortic valve replacement (TAVR) often have concomitant coronary artery disease (CAD) which may adversely affect prognosis. There is uncertainty about the benefits and the optimal timing of revascularization for such patients. There is currently clinical equipoise regarding the management of concomitant CAD in patients undergoing TAVR. Some centers perform routine revascularization with percutaneous coronary intervention (PCI) (either before or after TAVR), while others follow an alternative strategy of medical management.
Read full original descriptionShow less
The potential benefits and optimal timing of PCI in these patients are unknown. As TAVR expands to lower risk patients, and potentially becomes the preferred therapy for the majority of patients with severe aortic stenosis, the optimal management of concomitant coronary artery disease will be of increasing importance.
The COMPLETE TAVR study will determine whether, on a background of guideline-directed medical therapy, a strategy of complete revascularization involving staged PCI using drug eluting stents to treat all suitable coronary artery lesions is superior to a strategy of medical therapy alone in reducing the composite outcome of Cardiovascular Death, new Myocardial Infarction, Ischemia-driven Revascularization or Hospitalization for Unstable Angina or Heart Failure.
The study will be a randomized, multicenter, open-label trial with blinded adjudication of outcomes. Patients will be screened and consented for elective transfemoral TAVR and randomized within 96 hours of successful balloon expandable TAVR.
Complete Revascularization:
Staged PCI using third generation drug eluting stents to treat all suitable coronary artery lesions in vessels that are at least 2.5 mm in diameter and that are amenable to treatment with PCI and have a ≥70% visual angiographic diameter stenosis. Staged PCI can occur any time from 1 to 45 days post successful transfemoral TAVR.
Vs. Medical Therapy Alone:
No further revascularization of coronary artery lesions.
All patients, regardless of randomized treatment allocation, will receive guideline-directed medical therapy consisting of risk factor modification and use of evidence-based therapies. The COMPLETE TAVR study will help address the current lack of evidence in this area. It will likely impact both the global delivery of health care and the management and clinical outcomes of all patients undergoing TAVR with concomitant CAD.
The 2 groups in the trial
- Complete RevascularizationTreatment being tested
Routine PCI (percutaneous coronary intervention) of all suitable coronary artery stenoses of ≥70% in vessels ≥2.5mm in diameter.
Treatment: Percutaneous Coronary Intervention (PCI)
- Medical Therapy AloneNo study treatment, for comparison
No revascularization of coronary artery lesions.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Comparative Effectiveness Study of Staged Complete Revascularization With Percutaneous Coronary Intervention to Treat Coronary Artery Disease vs Medical Management Alone in Patients With Symptomatic Aortic Valve Stenosis Undergoing Elective Transfemoral Transcatheter Aortic Valve Replacement: The COMPLETE TAVR Study
- Plain-language title
- Tests stented heart artery treatment alongside valve replacement in people with aortic stenosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 24 July 2025